KRAS and colorectal carcinoma: We did additional subgroup analysis according to the stage, in patients KRAS-wt tumors and found patients with SLFN11high tumors had a trend of better survival than that with SLFN11low tumors in both stage II (Fig. 4a) and stage III CRC, more prominent in stage III (100 % vs 72 %, Log-rank P = 0.092, Fig. 4b).